Skip to main content
Premium Trial:

Request an Annual Quote

Cancer Diagnostics IP Plays Musical Chairs With Two Genzyme Divisions

NEW YORK, Jan 3 — One Genzyme business division has agreed to sell its cancer diagnostics intellectual property and licensing to another division, the company announced  on Thursday.

 

Under the deal, Genzyme Genetics acquired diagnostic rights for dozens of cancer markers from Genzyme Molecular Oncology, including p53 and the colon cancer-linked genes MSH2 and APC. The genetics division, which focuses on genetic testing and counseling, now assumes exclusive rights to the intellectual property and any licenses on cancer-related genes and diagnostic methods.

 

Genzyme Genetics will use the markers to develop and commercialize its own cancer tests, while simultaneously developing new non-exclusive licensing agreements with outside partners. The division will have further diagnostic rights to new cancer markers that Genzyme Molecular Oncology may discover in the future, and options on new findings made with its collaborative partners.

 

The molecular oncology division received $32 million in return, and may also get an additional $1 million in milestone payments. It will use that money to fund its programs in cancer vaccines and angiogenesis inhibition. That division's current cash balance is now approximately $40 million, which the company says is sufficient to fund its operations into 2003.

 

The deal "significantly increased our cash balance in a non-dilutive manner," Gail Maderis, Genzyme Molecular Oncology president, said in a statement.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.